Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial

Donel M. Martin, Shawn M. McClintock, Scott T. Aaronson, Angelo Alonzo, Mustafa M. Husain, Sarah H. Lisanby, William M. McDonald, Adith Mohan, Stevan Nikolin, John O'Reardon, Cynthia Shannon Weickert, Colleen K. Loo

Research output: Contribution to journalArticle

Abstract

Background: Transcranial direct current stimulation (tDCS) has promising antidepressant effects, however, clinical trials have shown variable efficacy. Pre-treatment neurocognitive functioning has previously been identified as an inter-individual predictor of tDCS antidepressant efficacy. Objective: In this international multicentre, sham-controlled study, we investigated this relationship while also assessing the influence of clinical and genotype (BDNF Val66Met and COMT Val158Met polymorphisms) factors as predictors of response to active tDCS. Methods: The study was a triple-masked, parallel, randomized, controlled design across 6 international academic medical centers. Participants were randomized to active (2.5 mA) or sham (34 μA) tDCS for 30 min each session for 20 sessions. The anode was centered over the left dorsolateral prefrontal cortex at F3 (10/20 EEG system) and the cathode over the lateral right frontal area at F8. Results: Better pre-treatment attentional processing speed on the Ruff 2 & 7 Selective Attention Test (Total Speed: β = 0.25, p <.05) and concurrent antidepressant medication use (β = 0.31, p <.05) predicted antidepressant efficacy with active tDCS. Genotype differences in the BDNF Val66Metand COMT Val158Met polymorphisms were not associated with antidepressant effects. Secondary analyses revealed that only participants in the highest performing Ruff 2 & 7 Total Speed group at pre-treatment in both active and sham tDCS conditions showed significantly greater antidepressant response compared to those with lower performance at both the 2 and 4 week treatment time points (p <.05). Conclusions: These results suggest that high pre-treatment attentional processing speed may be relevant for identifying participants more likely to show better tDCS antidepressant response to both high (2.5 mA) and very low (34 μA) current intensity stimulation. Clinical trials registration: www.clinicaltrials.gov, NCT01562184.

Original languageEnglish (US)
Pages (from-to)1282-1290
Number of pages9
JournalBrain Stimulation
Volume11
Issue number6
DOIs
StatePublished - Nov 1 2018

Fingerprint

Antidepressive Agents
Randomized Controlled Trials
Brain-Derived Neurotrophic Factor
Therapeutics
Electrodes
Genotype
Clinical Trials
Transcranial Direct Current Stimulation
Prefrontal Cortex
Electroencephalography

Keywords

  • Cognition
  • Depression
  • Genotype
  • Response
  • Transcranial direct current stimulation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biophysics
  • Clinical Neurology

Cite this

Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation : Results from an international randomized controlled trial. / Martin, Donel M.; McClintock, Shawn M.; Aaronson, Scott T.; Alonzo, Angelo; Husain, Mustafa M.; Lisanby, Sarah H.; McDonald, William M.; Mohan, Adith; Nikolin, Stevan; O'Reardon, John; Weickert, Cynthia Shannon; Loo, Colleen K.

In: Brain Stimulation, Vol. 11, No. 6, 01.11.2018, p. 1282-1290.

Research output: Contribution to journalArticle

Martin, Donel M. ; McClintock, Shawn M. ; Aaronson, Scott T. ; Alonzo, Angelo ; Husain, Mustafa M. ; Lisanby, Sarah H. ; McDonald, William M. ; Mohan, Adith ; Nikolin, Stevan ; O'Reardon, John ; Weickert, Cynthia Shannon ; Loo, Colleen K. / Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation : Results from an international randomized controlled trial. In: Brain Stimulation. 2018 ; Vol. 11, No. 6. pp. 1282-1290.
@article{3eb79a64f4bf42cf9823a7c240892924,
title = "Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial",
abstract = "Background: Transcranial direct current stimulation (tDCS) has promising antidepressant effects, however, clinical trials have shown variable efficacy. Pre-treatment neurocognitive functioning has previously been identified as an inter-individual predictor of tDCS antidepressant efficacy. Objective: In this international multicentre, sham-controlled study, we investigated this relationship while also assessing the influence of clinical and genotype (BDNF Val66Met and COMT Val158Met polymorphisms) factors as predictors of response to active tDCS. Methods: The study was a triple-masked, parallel, randomized, controlled design across 6 international academic medical centers. Participants were randomized to active (2.5 mA) or sham (34 μA) tDCS for 30 min each session for 20 sessions. The anode was centered over the left dorsolateral prefrontal cortex at F3 (10/20 EEG system) and the cathode over the lateral right frontal area at F8. Results: Better pre-treatment attentional processing speed on the Ruff 2 & 7 Selective Attention Test (Total Speed: β = 0.25, p <.05) and concurrent antidepressant medication use (β = 0.31, p <.05) predicted antidepressant efficacy with active tDCS. Genotype differences in the BDNF Val66Metand COMT Val158Met polymorphisms were not associated with antidepressant effects. Secondary analyses revealed that only participants in the highest performing Ruff 2 & 7 Total Speed group at pre-treatment in both active and sham tDCS conditions showed significantly greater antidepressant response compared to those with lower performance at both the 2 and 4 week treatment time points (p <.05). Conclusions: These results suggest that high pre-treatment attentional processing speed may be relevant for identifying participants more likely to show better tDCS antidepressant response to both high (2.5 mA) and very low (34 μA) current intensity stimulation. Clinical trials registration: www.clinicaltrials.gov, NCT01562184.",
keywords = "Cognition, Depression, Genotype, Response, Transcranial direct current stimulation",
author = "Martin, {Donel M.} and McClintock, {Shawn M.} and Aaronson, {Scott T.} and Angelo Alonzo and Husain, {Mustafa M.} and Lisanby, {Sarah H.} and McDonald, {William M.} and Adith Mohan and Stevan Nikolin and John O'Reardon and Weickert, {Cynthia Shannon} and Loo, {Colleen K.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.brs.2018.08.011",
language = "English (US)",
volume = "11",
pages = "1282--1290",
journal = "Brain Stimulation",
issn = "1935-861X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation

T2 - Results from an international randomized controlled trial

AU - Martin, Donel M.

AU - McClintock, Shawn M.

AU - Aaronson, Scott T.

AU - Alonzo, Angelo

AU - Husain, Mustafa M.

AU - Lisanby, Sarah H.

AU - McDonald, William M.

AU - Mohan, Adith

AU - Nikolin, Stevan

AU - O'Reardon, John

AU - Weickert, Cynthia Shannon

AU - Loo, Colleen K.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Transcranial direct current stimulation (tDCS) has promising antidepressant effects, however, clinical trials have shown variable efficacy. Pre-treatment neurocognitive functioning has previously been identified as an inter-individual predictor of tDCS antidepressant efficacy. Objective: In this international multicentre, sham-controlled study, we investigated this relationship while also assessing the influence of clinical and genotype (BDNF Val66Met and COMT Val158Met polymorphisms) factors as predictors of response to active tDCS. Methods: The study was a triple-masked, parallel, randomized, controlled design across 6 international academic medical centers. Participants were randomized to active (2.5 mA) or sham (34 μA) tDCS for 30 min each session for 20 sessions. The anode was centered over the left dorsolateral prefrontal cortex at F3 (10/20 EEG system) and the cathode over the lateral right frontal area at F8. Results: Better pre-treatment attentional processing speed on the Ruff 2 & 7 Selective Attention Test (Total Speed: β = 0.25, p <.05) and concurrent antidepressant medication use (β = 0.31, p <.05) predicted antidepressant efficacy with active tDCS. Genotype differences in the BDNF Val66Metand COMT Val158Met polymorphisms were not associated with antidepressant effects. Secondary analyses revealed that only participants in the highest performing Ruff 2 & 7 Total Speed group at pre-treatment in both active and sham tDCS conditions showed significantly greater antidepressant response compared to those with lower performance at both the 2 and 4 week treatment time points (p <.05). Conclusions: These results suggest that high pre-treatment attentional processing speed may be relevant for identifying participants more likely to show better tDCS antidepressant response to both high (2.5 mA) and very low (34 μA) current intensity stimulation. Clinical trials registration: www.clinicaltrials.gov, NCT01562184.

AB - Background: Transcranial direct current stimulation (tDCS) has promising antidepressant effects, however, clinical trials have shown variable efficacy. Pre-treatment neurocognitive functioning has previously been identified as an inter-individual predictor of tDCS antidepressant efficacy. Objective: In this international multicentre, sham-controlled study, we investigated this relationship while also assessing the influence of clinical and genotype (BDNF Val66Met and COMT Val158Met polymorphisms) factors as predictors of response to active tDCS. Methods: The study was a triple-masked, parallel, randomized, controlled design across 6 international academic medical centers. Participants were randomized to active (2.5 mA) or sham (34 μA) tDCS for 30 min each session for 20 sessions. The anode was centered over the left dorsolateral prefrontal cortex at F3 (10/20 EEG system) and the cathode over the lateral right frontal area at F8. Results: Better pre-treatment attentional processing speed on the Ruff 2 & 7 Selective Attention Test (Total Speed: β = 0.25, p <.05) and concurrent antidepressant medication use (β = 0.31, p <.05) predicted antidepressant efficacy with active tDCS. Genotype differences in the BDNF Val66Metand COMT Val158Met polymorphisms were not associated with antidepressant effects. Secondary analyses revealed that only participants in the highest performing Ruff 2 & 7 Total Speed group at pre-treatment in both active and sham tDCS conditions showed significantly greater antidepressant response compared to those with lower performance at both the 2 and 4 week treatment time points (p <.05). Conclusions: These results suggest that high pre-treatment attentional processing speed may be relevant for identifying participants more likely to show better tDCS antidepressant response to both high (2.5 mA) and very low (34 μA) current intensity stimulation. Clinical trials registration: www.clinicaltrials.gov, NCT01562184.

KW - Cognition

KW - Depression

KW - Genotype

KW - Response

KW - Transcranial direct current stimulation

UR - http://www.scopus.com/inward/record.url?scp=85052626140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052626140&partnerID=8YFLogxK

U2 - 10.1016/j.brs.2018.08.011

DO - 10.1016/j.brs.2018.08.011

M3 - Article

C2 - 30172724

AN - SCOPUS:85052626140

VL - 11

SP - 1282

EP - 1290

JO - Brain Stimulation

JF - Brain Stimulation

SN - 1935-861X

IS - 6

ER -